Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Heparegenix Raises €15 Million Series C Round To Advance Clinical Development Of Hrx 215 For Liver Regeneration is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
HepaRegeniX completes €21.5 million financing to support clinical ...
HepaRegeniX plans to use the proceeds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, the company’s lead clinical candidate in liver regeneration. Read More
HepaRegeniX completes €21.5 million financing to support clinical ...
Tuebingen, Germany, April 15, 2025 - HepaRegeniX GmbH ("HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing ... Read More
HepaRegeniX completes €21.5 million financing to support clinical ...
Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus